Haemonetics Corporation Stock News

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has acquired en

Medtronic (MDT) presents favorable study outcomes for its Evolut TAVR system, which is expected to offer better treatment options to low-risk bicuspid aortic valve stenosis patients.

Medtronic (MDT) presents favorable study outcomes for its Evolut TAVR system, which is expected to offer better treatment options to low-risk bicuspid aortic valve stenosis patients.

Haemonetics Corp:

Haemonetics Corporation (NYSE: HAE) today announced that it has appointed Anila Lingamneni Executive Vice President and Chief Technology Officer, effective April 1, 2020. She will report directly to C

Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Haemonetics (HAE) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Haemonetics names Anila Lingamneni as EVP, Chief Technology Officer HAE

Brokerages predict that Haemonetics Co. (NYSE:HAE) will announce sales of $246.31 million for the current quarter, Zacks reports. Three analysts have issued estimates for Haemonetics’ earnings, with

AQR Capital Management LLC decreased its holdings in shares of Haemonetics Co. (NYSE:HAE) by 49.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Comm

Co-Diagnostics (NASDAQ:CODX) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, pro

Morgan Stanley analyst David Lewis maintained a Buy rating on Haemonetics (HAE) today and set a price target of $138.00. The company's shares closed last